PDF
File
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Stockholm, March 4, 2024 - The composition of the Nomination Committee in Intervacc AB (publ) ("Intervacc") was announced in a Press Release on October 30, 2023. Due to the fact that Ulrika Enhörning, appointed by Swedbank Robur Fonder and Thomas Ehlin, appointed by Fjärde AP-fonden in December 2023 announced that they had chosen to resign from their assignment in the Nomination Committee, new members have been appointed to the Nomination Committee in accordance with the principles for appointing the Nomination Committee in Intervacc that were adopted at the Annual General Meeting on June 14, 2022.
- Magnus Lundberg, appointed by ownership group consisting of Håkan Björklund and Magnus Lundberg
- Christian Rudbäck, appointed by ownership group consisting of Jan-Ingmar Flock, NR Bergman Holding AB, Kenneth Janzon, Christian Rudbäck och Johan Virgin.
- Björn Sjöstrand, own possession.
The Nomination Committee together represent approximately 11,1 percent of the number of shares and votes in the company based on the shareholder information as of December 31, 2023.
The Nomination Committee's task is to prepare and submit proposals for the chairman of the board, other members of the board, board remuneration and any other remuneration to the board members as well as the election and remuneration of auditors for decision at the Annual General Meeting.
Shareholders who wish to submit proposals to the Nomination Committee can do so by sending an e-mail to shareholders@intervacc.se(heading - "Nomination Committee") or by letter posted to Intervacc AB (publ), Attn: Intervacc Nomination Committee, Box 112, SE-129 22 Stockholm, Sweden.
For more information please contact:
Jonas Sohlman, CEO
Phone: +46 (0)8 120 10 600
E-mail: info@intervacc.se
The information was submitted for publication, through the agency of the contact person set out above on March 4, 2024, 15.30 CET.
About Intervacc
Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se,Phone: +46 (0)8 - 684 211 10